Blog

“Jack Kirby: From the Ghetto to the Cosmos’

NEW YORK CITY, NEW YORK / ACCESS Newswire / November 26, 2025 / One Art Space, Tribeca, NY, is proud to announce the return of Jack Kirby Museum and Research Center. The Jack Kirby Museum and Research Center is back in New York City with a new pop-up display celebrating the life, influences, and lasting legacy of the King of Comics. “Jack Kirby: From the Ghetto to the Cosmos” will run for one week at One Art Space from Friday, Nov. 28, through Sunday, Dec. 7, 2025. “It is truly an honor to have the Jack Kirby Museum exhibit here at One Art Space,” said MaryAnn Giella McCulloh, co-owner of One Art Space.

Tracking Jacob Kurtzberg’s life, starting as an impoverished Jewish boy in NYC’s teeming Lower East Side and ending as a master of imagination for pop culture giants like Marvel and DC, influencing millions, “Jack Kirby: From the Ghetto to the Cosmos” features displays that tell biographical details, show the finer details of his artwork and process, and present familiar works at larger scale. The pop-up display will span the length of Kirby’s fascinating life and career, from his “Kid Gang” stories to the cosmic wonder of his Fantastic Four, Silver Surfer, and Thor at Marvel, and his later sci-fi epics such as DC’s New Gods and Forever People and his stunning Lord of Light work.

EXHIBITION: Friday, Nov. 28 – Sunday, Dec. 7, 12-6 p.m.
OPENING RECEPTION: Saturday, Nov. 29, 6-9 p.m.
WHERE: One Art Space, 23 Warren Street, New York, NYC (Tribeca)
ADMISSION: $5 Suggested Donation (Kirby Museum Members FREE!)

The Jack Kirby Museum and Research Center is organized exclusively for educational purposes; more specifically, to promote and encourage the study, understanding, preservation and appreciation of the work of Jack Kirby by illustrating the scope of Kirby’s multi-faceted career, communicating the stories, inspirations and influences of Jack Kirby, celebrating the life of Jack Kirby and his creations, and building understanding of comic books and comic book creators.

Information: www.kirbymuseum.org | IG: @jackkirbymuseum |

One Art Space opened in May 2011, in the heart of Tribeca, NY and has both museum-caliber and emerging artists for 15 years. Located at 23 Warren Street in Tribeca, New York City, the gallery occupies a ground-level space with a glass façade, natural light and an inviting view from the street. The gallery mixes storied figures in New York’s art scene like Al Diaz, world-famous street artists like Shepard Fairey, abstract painters Andrew Salgado, and coming in February 2026, the solo exhibition of work by Purvis Young, whose paintings are held in prestigious institutions like The Metropolitan Museum of Art, the Smithsonian, and the Whitney as well as in many private collections. Our mission is to create a place where the giants of art history and the visionaries of art’s future come together in One Art Space.

Information: www.oneartspace.com | IG: @oneartspace | F: OneArtSpaceNYC |

Contact Information

MaryAnn Giella McCulloh
Co-Owner, Gallerist and Curator
info@oneartspace.com
(646) 559-0535

Randolph Hoppe
Director
info@kirbymuseum.org
(201) 204-0532

SOURCE: One Art Space

View the original press release on ACCESS Newswire

NEW YORK CITY, NEW YORK / ACCESS Newswire / November 26, 2025 / The room at DMCC yesterday was not a casual audience. It was the gravitational center of the modern gold economy. Dubai’s DMCC sits at the crossroads of global bullion trading, refinery flows, vaulting networks, and cross-border logistics. When an organization of that stature gives the microphone to a verification company, the message is not symbolic. It means the industry sees a structural shift forming. SMX (NASDAQ:SMX) delivered that shift.

The presentation cut through the noise with a simple idea that landed harder in Dubai than anywhere else. Gold is only as valuable as its verified origin. Every trade, every premium, every audit, every cross-border movement depends on truth under pressure. That is why the DMCC Precious Metals Conference was the right stage. No other global hub carries the same influence over how trust is priced in precious metals. And no other technology has shown what SMX showed yesterday. Gold can now carry an identity that survives the entire chain of custody without external markers or human interpretation.

The significance is larger than the event. DMCC is the bridge between East and West for bullion. It is where traders look for clarity when markets tighten. It is where refineries and logistics companies decide how to modernize. When SMX demonstrated molecular memory in that environment, it was not an introduction. It was a declaration that the gold market now has a new standard. Goldstrom’s early integration already proved the appetite. DMCC’s platform proved the inevitability.

The Broader Gold Standard

What happened in that room was not about gold alone. It was gold validating the foundation for every other sector SMX touches. Gold has always been the stress test because nothing exposes weakness faster. If SMX’s chemistry withstands the refinery furnace, the transport chain, the melting pot, and the vault inspection, it withstands anything. That is why the DMCC audience leaned in. Once gold accepts a technology, commodities that operate on thinner margins and tougher environments follow quickly.

Natural rubber is the perfect example. SMX’s verification of twenty-one tons from tree to tire would be impressive in isolation. After DMCC, it becomes something else. It becomes parallel proof that the same verification layer that secures a bar of bullion can secure a commodity that is volatile, organic, chemically reactive, and shaped by global trade. That continuity across materials was clearer yesterday than ever before. Gold proves purity. Rubber proves scale.

Textiles picked up the same energy. Brands are preparing for digital passport laws. Regulators are tightening audit requirements. Circular fashion is becoming more than marketing. SMX’s textile partnerships now sit in the same framework that gold traders saw in Dubai. A material with embedded truth commands premiums. It trades cleaner. It moves faster. DMCC’s authority amplified this point. If the gold industry is heading toward molecular verification, apparel will not be far behind.

Rare Earths, Electronics; It’s All In Play

Rare earths and critical minerals were not the headline of the presentation, but they were part of the subtext. The audience understood the geopolitical undertone. Nations cannot build energy security or technology independence without clarity in their mineral supply chains. SMX’s ability to prevent substitution or tampering at the chemical level fits directly into that conversation. Dubai, as a global trading hub, sees these flows long before most markets do. The DMCC crowd recognized the strategic relevance immediately.

Electronics rounded out the picture. The world’s biggest vulnerability sits in hardware. It is invisible, expensive, and growing. SMX positions itself as the point of truth before a component enters an assembly line. For the DMCC audience, that closed the loop. The same system that protects gold from fraud protects microchips from infiltration. It is not a luxury. It is a necessity.

Yesterday’s presentation clarified something the market already sensed. SMX is not building use cases. It is building an industrial standard. Gold simply provided the stage with the most authority. DMCC provided the microphone with the most reach. Everything else followed naturally. Every partnership fits the same trajectory. Every sector is converging on proof. And SMX is the company delivering it.

About SMX

As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.

Forward-Looking Statements

The information in this press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “will,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release may include, for example: matters relating to the Company’s fight against abusive and possibly illegal trading tactics against the Company’s stock; successful launch and implementation of SMX’s joint projects with manufacturers and other supply chain participants of steel, rubber and other materials; changes in SMX’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; SMX’s ability to develop and launch new products and services, including its planned Plastic Cycle Token; SMX’s ability to successfully and efficiently integrate future expansion plans and opportunities; SMX’s ability to grow its business in a cost-effective manner; SMX’s product development timeline and estimated research and development costs; the implementation, market acceptance and success of SMX’s business model; developments and projections relating to SMX’s competitors and industry; and SMX’s approach and goals with respect to technology. These forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing views as of any subsequent date, and no obligation is undertaken to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: the ability to maintain the listing of the Company’s shares on Nasdaq; changes in applicable laws or regulations; any lingering effects of the COVID-19 pandemic on SMX’s business; the ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which SMX operates; the risk that SMX and its current and future collaborators are unable to successfully develop and commercialize SMX’s products or services, or experience significant delays in doing so; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that SMX is unable to secure or protect its intellectual property; the possibility that SMX may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties described in SMX’s filings from time to time with the Securities and Exchange Commission.

Contact: info@securitymattersltd.com

SOURCE: SMX (Security Matters) Public Limited

View the original press release on ACCESS Newswire

Moderated webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Wednesday, December 3^rd at 4:00 PM ET

IRVINE, CA / ACCESS Newswire / November 26, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) (“enVVeno Medical” or the “Company”), today announced that Robert Berman, Chief Executive Officer of enVVeno Medical will participate in a Live Virtual Investor CEO Connect segment on Wednesday, December 3, 2025 at 4:00 PM ET.

As part of the event, Mr. Berman will provide a corporate overview and discuss the Company’s recent news and next steps. In addition to the moderated discussion, there will be a live question and answer session. Mr. Berman will answer as many questions as possible in the time allowed.

A live video webcast of the presentation will be available on the Events page of the Company’s website (www.envveno.com). A webcast replay will be available two hours following the live event and will be accessible for 90 days.

About enVVeno Medical Corporation

enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease.

Cautionary Note on Forward-Looking Statements

This press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the “Company”) related thereto contain, or may contain, among other things, certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential” or similar expressions. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results and timing (may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

###

INVESTOR CONTACT:

Jenene Thomas, JTC Team, LLC
NVNO@jtcir.com
(908) 824-0775

MEDIA CONTACT:
Glenn Silver, FINN Partners
Glenn.Silver@finnpartners.com
(973) 818-8198

SOURCE: enVVeno Medical Corporation

View the original press release on ACCESS Newswire

ORLANDO, FLORIDA / ACCESS Newswire / November 26, 2025 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced its upcoming Metals & Mining: The Race to Onshore Critical Minerals Virtual Investor Conference, taking place December 10, 2025, from 9:30 a.m. to 4:00 p.m. ET. The conference offers investors a front-row seat to the public companies driving exploration, development, and production across the rapidly evolving critical minerals sector.

Registration is free and open to the public: https://www.redchip.com/webinar/redchip/85823325098

“The global drive to onshore critical minerals has created one of the most compelling investment themes of this decade,” said Dave Gentry, CEO of RedChip Companies. “From rare earths to battery metals, demand continues to accelerate across clean energy, defense, and advanced manufacturing. This conference gives investors direct access to the public companies working to meet that demand and build the next generation of domestic strategic mineral supply chains.”

The virtual conference will feature presentations from CEOs and senior executives leading exploration, development, and production efforts across the critical minerals landscape. Each presentation will be followed by a live Q&A session, giving investors the opportunity to engage directly with company leadership.

Presenting Companies Include (partial list):

• ASP Isotopes (Nasdaq: ASPI)

• Nova Minerals (Nasdaq: NVA)

• Titan Mining Corporation (NYSE American: TII)

• Foremost Clean Energy (Nasdaq: FMST)

• 5E Advanced Materials (Nasdaq: FEAM)

View the full schedule and register here: https://www.redchip.com/webinar/redchip/85823325098

What Investors Will Gain

The conference offers investors a focused, high-value opportunity to learn about:

• Companies working to secure and expand critical mineral supply chains

• Key milestones, near-term objectives, and long-term development plans

• Major market catalysts shaping the sector

Whether institutional, family office, retail, or analyst, attendees will obtain concise, actionable insights into emerging opportunities across one of the fastest-moving thematic sectors in today’s markets.

About RedChip Companies

RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. Founded in 1992 as a small-cap research firm, RedChip gained early recognition for initiating coverage on emerging blue chip companies such as Apple, Starbucks, Daktronics, Winnebago, and Nike. Over the past 33 years, RedChip has evolved into a full-service investor relations and media firm, delivering concrete, measurable results for its clients, which have included U.S. Steel, Perfumania, Cidara Therapeutics, and Celsius Holdings, among others. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. RedChip also offers RedChat™, a proprietary AI-powered chatbot that analyzes SEC filings and corporate disclosures for all Nasdaq and NYSE-listed companies, giving investors instant, on-demand insights.

To learn more about RedChip’s products and services, please visit:

“Discovering Tomorrow’s Blue Chips Today”^™

Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/

Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies

Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/

Follow RedChip on Twitter: https://twitter.com/RedChip

Follow RedChip on YouTube: https://www.youtube.com/@redchip

Follow RedChip on Rumble: https://rumble.com/c/c-3068340

Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest

Contact:

Dave Gentry
RedChip Companies Inc.
1-800-REDCHIP (733-2447)
1-407-644-4256
info@redchip.com

SOURCE: RedChip Companies, Inc.

View the original press release on ACCESS Newswire

ESTERO, FL / ACCESS Newswire / November 26, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) (“Aspire” or the “Company”), a developer of a multi-faceted patent-pending drug delivery technology, has expanded its scientific team with the November 4, 2025 addition of Mark J. Jaroszeski, PhD, a tenured professor in the Department of Medical Engineering at the University of South Florida. Dr. Jaroszeski, who holds a PhD in Engineering Science with a dissertation focused on mechanically facilitated cell-cell electrofusion.

“Dr. Jaroszeski is recognized globally for his pioneering work in DNA and drug delivery, and we are honored to welcome him to the Aspire team,” said Kraig Higginson, Interim CEO of Aspire Biopharma. “He brings extensive experience in medical delivery systems that will be instrumental in advancing Aspire’s proprietary sublingual delivery technology. His insight and track record of innovation will play a critical role as we continue to develop and optimize our platform, building on our initial pipeline and extending these benefits to a broader range of generic medicines.”

Mark J. Jaroszeski, Ph.D., is Professor of Medical Engineering at the University of South Florida College of Engineering. Dr. Jaroszeski is a leading innovator in developing DNA/drug delivery technologies and methods to treat disease. He was one of the early pioneers performing in vivo electroporation during the early 1990’s, and was among the first researchers to develop basic electrodes and pulsing protocols to deliver chemotherapeutic agents to tumors in animal models in vivo, safely and effectively, with very strong anti-tumor effects. His work on the frontiers of DNA/drug delivery over the past 20 years laid the foundation for more than 100 current clinical trials using gene delivery. He holds 34 U.S. patents, 12 of which have been licensed to 7 companies. He is also currently Vice President of Research for EF Therapeutics, Inc., a start-up company focused on DNA delivery and translating it to the human and veterinary clinical markets. He has published 62 articles in peer-reviewed journals, two books and 11 book chapters, and presented at more than 114 conferences worldwide. He serves as a manuscript reviewer for 21 journals, as well as frequent reviewer for the National Institutes of Health. He has organized/chaired seven professional conferences, and is a delegate to the International Bioelectrics Consortium, a collection of research groups from about 15 countries.

About Aspire Biopharma Holdings, Inc.
Aspire Biopharma has developed a patent-pending sublingual delivery technology that can deliver drugs to the body rapidly and precisely. This technology offers the potential to improve effectiveness and reduce side effects by going directly to the bloodstream and avoiding the gastrointestinal tract. Aspire Biopharma’s delivery technology can be applied to many different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning both small and large molecule therapeutics, nutraceuticals and supplements.

For more information, please visit www.aspirebiolabs.com

Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the “safe harbor” provisions created by those laws. Aspire’s forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; and other risks and uncertainties set forth in “Risk Factors” in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

Aspire Biopharma Holdings, Inc.
Contact
Brett Maas
Hayden IR: (646) 536-7331
brett@haydenir.com

James Carbonara
Hayden IR: (646)-755-7412
james@haydenir.com

SOURCE: Aspire Biopharma Holdings, Inc.

View the original press release on ACCESS Newswire

TORONTO, ON / ACCESS Newswire / November 26, 2025 / New Horizon Aircraft Ltd. (NASDAQ:HOVR), doing business as Horizon Aircraft (“Horizon Aircraft” or the “Company”), an advanced aerospace engineering company and developer of one of the world’s first hybrid electric VTOL (Vertical Take-Off and Landing) aircraft, announces that esteemed test pilot-astronaut Jameel Janjua has joined its Board of Directors, bringing deep expertise in experimental test flight, military operations, aerospace engineering, and business growth.

Jameel is a world-leading expert in experimental test flight and has provided leadership for space missions, billion-dollar aerospace programs, and has been an advisor to aerospace startups as they navigate through technical and business milestones.

Formerly serving as a fighter pilot in the Royal Canadian Air Force and as an instructor at USAF Test Pilot School, Jameel moved on to become an experimental test pilot with more than 5,500 hours flown in more than 65 aircraft. Currently he is a test pilot for Virgin Galactic, an aerospace and space travel company pioneering human spaceflight.

“Horizon Aircraft is revolutionizing regional air mobility with its hybrid electric, fan-in-wing VTOL design,” stated Jameel. “The Cavorite X7 has the ability to provide enhanced solutions for both civilian and military missions, and by joining the Board I can help ensure our business execution strategy is tightly aligned with delivering the safest possible certified aircraft.”

Jameel holds a Bachelor of Engineering from the Royal Military College of Canada, a Master of Science from MIT in Aeronautics and Aeronautics and recently earned an MBA from The Wharton School. His knowledge and extensive experience with aerospace flight and business operations will be a valuable addition to Horizon Aircraft’s Board of Directors as the Company builds its full-scale prototype and prepares it to undergo the aircraft certification process.

Horizon Aircraft Co-Founder and CEO Brandon Robinson stated, “Jameel joining our Board is a huge win for our team in more ways than one. Having someone of his caliber provide insight and mentorship will help us make the Cavorite X7 a leader in aerospace safety and be ready to fly real-world missions.”

For more information about Horizon Aircraft, please see the Company’s website or watch its innovative technology in action on the Company’s YouTube channel . Information on the New Horizon’s website does not constitute a part of and is not incorporated by reference into this press release.

About Horizon Aircraft

Horizon Aircraft (NASDAQ: HOVR) is an advanced aerospace engineering company that is developing one of the world’s first hybrid eVTOL designed to fly most of its mission exactly like a normal aircraft while offering industry-leading speed, range, and operational utility. Horizon Aircraft’s unique designs put the mission first and prioritize safety, performance, and utility. Horizon Aircraft intends to successfully complete testing and certification of its Cavorite X7 eVTOL and then scale unit production to meet expected demand from regional operators, emergency service providers, and military customers.

For further information, visit:

Website www.horizonaircraft.com
LinkedIn https://www.linkedin.com/company/horizon-aircraft-inc

For further information, contact:

Investors:
Matt Chesler, CFA
FNK IR LLC
(646) 809-2183
HOVR@fnkir.com

Media:
Edwina Frawley-Gangahar
EFG Media Relations
+44 7580 174672
edwina@efgmediarelations.com

Forward-Looking Statements

This press release contains certain “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of applicable Canadian securities laws (collectively, “forward-looking statements”). These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “aim,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “target,” “will be,” “will continue,” “will likely result” and similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements herein include, but are not limited to, statements relating to the targeted readiness of the full-scale hybrid Cavorite X7 eVTOL prototype for initial testing, development priorities and technical milestones; funding and liquidity sufficiency and runway; certification and testing plans; and potential production, partnership, supply chain and market opportunities.

Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) changes in the markets in which Horizon Aircraft competes, including with respect to its competitive landscape, technology evolution or regulatory changes; (ii) the risk that Horizon Aircraft will need to raise additional capital to execute its business plans, which may not be available on acceptable terms or at all; (iii) the lack of useful financial information for an accurate estimate of future capital expenditures and future revenue; (iv) statements regarding Horizon Aircraft’s industry and market size; (v) financial condition and performance of Horizon Aircraft, including the condition, liquidity, results of operations, the products, the expected future performance and market opportunities of Horizon Aircraft; (vi) Horizon Aircraft’s ability to develop, certify, and manufacture an aircraft that meets its performance expectations; (vii) successful completion of testing and certification of Horizon Aircraft’s Cavorite X7 eVTOL; (viii) the targeted future production of Horizon Aircraft’s Cavorite X7 aircraft; and (ix) other factors detailed by us in the Company’s public filings with the Securities and Exchange Commission (“SEC”) and under the Company’s profile on sedarplus.ca, including the disclosures under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended May 31, 2025, filed with the SEC and filed under the Company’s profile on sedarplus.ca on August 22, 2025. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made.

Readers are cautioned not to put undue reliance on forward-looking statements, and while the Company may elect to update these forward-looking statements at some point in the future, it assumes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by applicable law. Horizon Aircraft does not give any assurance that Horizon Aircraft will achieve its expectations.

SOURCE: Horizon Aircraft

View the original press release on ACCESS Newswire

• Company plans to distribute Dream Bowl 2026 Meme Coin to shareholders as of a to-be-determined December 2025 date with distribution expected in January 2026

TAMPA, FLORIDA / ACCESS Newswire / November 26, 2025 / Wellgistics Health, Inc. (“Wellgistics”) (NASDAQ:WGRX), a health information technology leader implementing EinsteinRx™ artificial intelligence prescription routing for the physical dispensing of prescription drugs with PharmacyChain™ blockchain-enabled smart contracts to optimize the tracking, dispending and insurance coverage of prescription pharmaceutical drugs from manufacturer to dispensing from pharmacy to patient, today announced that it is sponsoring Dream Bowl 2026 and participation in the DataVault AI (NASDAQ:DVLT) Shareholder Distribution Plan. The Company expects to set (1) a record date and (2) a distribution date for the Dream 2026 Meme Coin to its shareholders; both are expected to occur in December 2025.

Dream Bowl 2026 is a marquee event that will culminate on January 11, 2026, at AT&T Stadium in Dallas, Texas, where elite athletes will compete for the Dream Bowl Championship. The Dream Bowl 2026 Meme Coin is a digital collectible intended to provide for immutable recognition of ownership and utility with ticketing information and embed exclusive details on invited athletes, game highlight, accepted invitations and event insights, serving as a unique token of participation in this groundbreaking spectacle. Handcrafted ditigal coins will be airdropped directly to DataVault wallets for Wellgistics shareholders on or after the to-be-determined record date. Wellgistics shareholders will receive detailed information about how to register and set wallets in the DataVault system and instructions on how to trade these meme coins upon setting up the distribution date of these meme coins.

About Datavault AI Inc.

Datavault AI™ (Nasdaq: DVLT) is leading the way in AI driven data experiences, valuation, and monetization of assets in the Web 3.0 environment. The Company’s cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Science and Data Science Divisions. Datavault AI’s Acoustic Science Division features WiSA®, ADIO® and Sumerian® patented technologies and industry-first foundational spatial and multichannel wireless HD sound transmission technologies with IP covering audio timing, synchronization, and multi-channel interference cancellation. The Data Science Division leverages the power of Web 3.0 and high-performance computing to provide solutions for experiential data perception, valuation, and secure monetization. Datavault AI’s cloud-based platform provides comprehensive solutions serving multiple industries, including HPC software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy and more. The Information Data Exchange® (IDE) enables Digital Twins, licensing of name, image, and likeness (NIL) by securely attaching physical real-world objects to immutable metadata objects, fostering responsible AI with integrity. Datavault AI’s technology suite is completely customizable and offers AI and Machine Learning (ML) automation, third-party integration, detailed analytics and data, marketing automation, and advertising monitoring. The Company is headquartered in Philadelphia, PA.

Learn more about Datavault AI at www.dvlt.ai.

About Dream Bowl 2026 Meme Coin

The Dream Bowl 2026 Meme Coin is a digital collectible intended solely for personal, non-commercial use in connection with the Dream Bowl 2026 event. The Meme Coin does not: (i) represent or confer any equity, voting, dividend, profit-sharing, or ownership rights in Wellgistics or any other entity; (ii) provide any right to receive monetary payments, distributions, or appreciation; or (iii) create any expectation of profit or reliance on the managerial or entrepreneurial efforts of Wellgistics or others. The Meme Coin is not designed or intended to function as an investment, currency, or financial product, and it is not being offered, sold, or distributed for fundraising or capital-raising purposes. The Meme Coin is not intended to be a ‘security’ as that term is defined under the Securities Act of 1933, the Securities Exchange Act of 1934, or any applicable state securities laws. Use of the Meme Coin is limited to entertainment, event-access, and digital-collectible functions. Any transferability features are provided solely to support personal digital item portability and not to facilitate or imply investment or speculative use.

About Wellgistics Health, Inc.

Wellgistics Health (NASDAQ: WGRX) is physical and technology pharmacy-enabling health IT company that specializes in optimizing the delivery medications from manufacturers to patients. Its integrated platform connects 6,500+ pharmacies and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment. Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in U.S. healthcare.

For more information, visit www.wellgisticshealth.com.

Forward-Looking Statements

This press release contains forward‑looking statements within the meaning of the federal securities laws, including, without limitation, statements regarding the parties’ plans to negotiate definitive agreements, potential implementation, adoption, performance, revenue sharing, and other anticipated benefits of the contemplated collaboration. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including those described in DataVault AI, Inc.’s and Wellgistics Health, Inc.’s filings with the SEC. Forward‑looking statements speak only as of the date hereof, and neither company undertakes any obligation to update them except as required by law. Additional factors are discussed in Wellgistics Health’s filings with the SEC, available at www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction, and there shall be no sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Wellgistics Media & Investor Contact

Media:
media@wellgisticshealth.com

Investor Relations:
IR@wellgisticshealth.com

Wellgistics Investor Relations Contact

Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor
New York, NY 10036
Office: (646) 893-5835
Email: info@skylineccg.com

DataVault Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com

Media Inquiries:
marketing@dvlt.ai

SOURCE: Wellgistics Health, Inc.

View the original press release on ACCESS Newswire